Amylin Pharmaceuticals Reviews

3.8
Rating Trends
Recommend to a friend
Approve of CEO
Amylin Pharmaceuticals President, CEO, and Director Dan Bradbury
Dan Bradbury
67 Ratings
  • Finance

    • Work/Life Balance
    • Culture & Values
    • Career Opportunities
    • Comp & Benefits
    • Senior Management
    Former Employee - Anonymous Employee
    Former Employee - Anonymous Employee

    Pros

    Challenging work. Great benefits and compensation package.

    Cons

    Not all promotions were merited.


Amylin Pharmaceuticals Interviews

Interview Experience

Interview Experience

55%
33%
11%

Getting an Interview

Getting an Interview

57%
28%
14%

Interview Difficulty

2.7
Average

Interview Difficulty

Hard

Average

Easy
  1.  

    Diabetes Sales Specialist Interview

    Anonymous Employee in Jersey City, NJ
    No Offer
    Negative Experience
    Average Interview

    Application

    I applied through a recruiter. The process took 4 days. I interviewed at Amylin Pharmaceuticals (Jersey City, NJ).

    Interview

    Contacted by recruiter to do a multi-person interview at a Hyatt hotel. Was basically a cattle call type set-up with tons of people being shifted to HR, marketing and management in different areas of the hotel. Very unorganized and highly unprofessional. Final IV with manager was a sad joke.

    Interview Questions

    • "If I gave you this pencil, do you think you could close for the business and get me to buy it?"   Answer Question

Amylin Pharmaceuticals Awards & Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Unlock Profile
Website www.amylin.com
Headquarters San Diego, CA
Size 1000 to 5000 Employees
Acquired By Bristol-Myers Squibb
Founded 1987
Type Subsidiary or Business Segment
Industry Biotech & Pharmaceuticals
Revenue $100 to $500 million (USD) per year

Amylin Pharmaceuticals helps diabetics gain the upper hand in their battle with the disease. The company makes and markets injectable diabetes drugs Byetta and Symlin, which are approved as adjunct therapies to other diabetes treatments such as metformin and insulin. Byetta is also approved as a stand-alone diabetes therapy. Amylin gained FDA approval for Bydureon, a once-weekly version of Byetta, in 2012, and it is developing additional drugs for metabolic conditions. The company's US sales force markets its products to patients and physicians; development partner ... More

Work at Amylin Pharmaceuticals? Share Your Experiences

Amylin Pharmaceuticals

 
Click to Rate
or